Recent advances in anti-infective drug discovery最新文献_第9页

A study on the bio-responses of a freshwater snail (Biomphalaria alexandrina) to fungal derived compounds. 淡水蜗牛(Biomphalaria alexandrina)对真菌衍生化合物的生物反应研究。

Recent advances in anti-infective drug discovery

Pub Date : 2022-06-10 DOI: 10.2174/2772434417666220610110226

A. Mekawey, Salah A R, Mohammed Yosri

BACKGROUNDBiomphalaria alexandrina snails, as transitional hosts of schistosomiasis, plays an essential part in spread of the illness. Control of these snails by the substance molluscicides antagonistically influences the oceanic climate, causing poisonous and cancer-causing consequences for non-target life forms.OBJECTIVELooking for new naturally safe substances can be used for treatment of schistosomiasis disease with minimal side effects on environment and plants, fish wealth and did not affect on human vital functions.METHODSFifty fungal species were used to evaluate their activity against Biomphalaria alexandrina. Study the effect of fungal extract on vital functions of Biomphalaria alexandrina and fish wealth. Purification of active substances and identification of their chemical structures. Results Cladosporium nigrellum and Penicillium aurantiogresium metabolites were effective against B. alexandrina snails, the effects of promising fungal extracts sub-lethal concentrations (IC10 & IC25) on the levels of steroid sex hormones, liver enzymes, total protein, lipids, albumin and glucose were determined. Chemical analyses of this filtrate resulted in the separation of a compound effective against snails; it was identified. Protein electrophoresis showed that fungal filtrate affects the protein pattern of snails' haemolymph. Little or no mortality of Daphnia pulex individuals was observed after their exposure to sub lethal concentrations of each treatment.CONCLUSIONCertain compounds from fungal cultures could be safely used for biological control of Biomphalaria alexandrina snails.

背景亚历山大生物phalaria alexandrina蜗牛作为血吸虫病的过渡宿主，在血吸虫病的传播中起着重要作用。用杀螺剂控制这些蜗牛会对海洋气候产生拮抗作用，对非目标生命形式造成有毒和致癌的后果。目的寻找对环境、植物、鱼类健康、不影响人体生命功能的天然安全的治疗血吸虫病的新物质。方法对50种真菌进行抑菌活性评价。研究了真菌提取物对绿藻生命功能和鱼类财富的影响。活性物质的纯化及其化学结构的鉴定。结果黑枝孢霉和金黄色青霉代谢产物对绿僵螺旋体钉螺有一定的杀伤作用，并测定了有潜力的真菌提取物亚致死浓度(IC10和IC25)对钉螺体内类固醇性激素、肝酶、总蛋白、血脂、白蛋白和葡萄糖水平的影响。对该滤液进行化学分析，分离出一种对蜗牛有效的化合物;它被确认了。蛋白电泳结果表明，真菌滤液对钉螺血淋巴蛋白结构有影响。在暴露于每一种处理的亚致死浓度后，观察到水蚤个体很少或没有死亡。结论从真菌培养物中提取的某些化合物可安全用于山绿螺的生物防治。

{"title":"A study on the bio-responses of a freshwater snail (Biomphalaria alexandrina) to fungal derived compounds.","authors":"A. Mekawey, Salah A R, Mohammed Yosri","doi":"10.2174/2772434417666220610110226","DOIUrl":"https://doi.org/10.2174/2772434417666220610110226","url":null,"abstract":"BACKGROUND\u0000Biomphalaria alexandrina snails, as transitional hosts of schistosomiasis, plays an essential part in spread of the illness. Control of these snails by the substance molluscicides antagonistically influences the oceanic climate, causing poisonous and cancer-causing consequences for non-target life forms.\u0000\u0000\u0000OBJECTIVE\u0000Looking for new naturally safe substances can be used for treatment of schistosomiasis disease with minimal side effects on environment and plants, fish wealth and did not affect on human vital functions.\u0000\u0000\u0000METHODS\u0000Fifty fungal species were used to evaluate their activity against Biomphalaria alexandrina. Study the effect of fungal extract on vital functions of Biomphalaria alexandrina and fish wealth. Purification of active substances and identification of their chemical structures. Results Cladosporium nigrellum and Penicillium aurantiogresium metabolites were effective against B. alexandrina snails, the effects of promising fungal extracts sub-lethal concentrations (IC10 & IC25) on the levels of steroid sex hormones, liver enzymes, total protein, lipids, albumin and glucose were determined. Chemical analyses of this filtrate resulted in the separation of a compound effective against snails; it was identified. Protein electrophoresis showed that fungal filtrate affects the protein pattern of snails' haemolymph. Little or no mortality of Daphnia pulex individuals was observed after their exposure to sub lethal concentrations of each treatment.\u0000\u0000\u0000CONCLUSION\u0000Certain compounds from fungal cultures could be safely used for biological control of Biomphalaria alexandrina snails.","PeriodicalId":74643,"journal":{"name":"Recent advances in anti-infective drug discovery","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82306242","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Design, Synthesis, Anti-microbial and Molecular Docking Studies of Novel 5-Pyrazyl-2-Sulfanyl-1, 3, 4-Oxadiazole Derivatives. 新型5-吡唑-2-磺胺基- 1,3,4 -恶二唑衍生物的设计、合成、抗菌及分子对接研究。

Recent advances in anti-infective drug discovery

Pub Date : 2022-06-09 DOI: 10.2174/2772434417666220609105755

R. Das, D. Mehta, Sumeet Gupta, Meenakshi Dhanawat

BACKGROUNDChemical modification of Oxadiazole may lead to a potent therapeutic agent. A series of novel 5-pyrazyl-2-sulfanyl-1, 3, 4-oxadiazole derivatives (5a-g) have been synthesised utilising pyrazinoic acid as a precursor. The new oxadiazole compounds were docked against potential targets and evaluated for antibacterial and antitubercular activity.METHODSThe 5-pyrazyl-2-substituted sulfanyl-1,3,4-oxadiazole derivatives (5a-g) were synthesized from the crucial intermediate 2-sulfanyl-5-pyrazyl-1,3,4-oxadiazole (4), which was prepared by treating the 2-pyrazyl hydrazide with CS2 and pyridine. IR, 1HNMR, 13C, MS and elemental analyses were used to confirm the chemical structures.RESULTSAntimicrobial activity was determined for each synthesized compound. Additionally, compounds were evaluated for antitubercular activity against the Mycobacterium Tuberculosis H37Rv strain. Compounds 5c, 5g, and 5a had a favourable antibacterial profile, while 5c and 5g (MIC = 25 g/ml) demonstrated potential antitubercular activity when compared to the other produced compounds. Molecular docking experiments using V-Life Science MDS 4.6 supplemented the biological data.CONCLUSIONEach compound has been tested for antibacterial and antitubercular action against a variety of microorganism strains and exhibits considerable activity. Additionally, molecular docking analysis confirmed the experimental results by describing improved interaction patterns.

背景:对恶二唑进行化学修饰可制成一种有效的治疗剂。以吡嗪酸为前体合成了一系列新的5-吡唑-2-磺胺基- 1,3,4 -恶二唑衍生物(5a-g)。新的恶二唑类化合物与潜在靶点对接，并对其抗菌和抗结核活性进行了评价。方法以关键中间体2-磺酰-5-吡唑-1,3,4-恶二唑(4)为原料，用CS2和吡啶处理2-吡唑肼，合成5-吡唑-2-取代磺酰-1,3,4-恶二唑衍生物(5a-g)。用IR、1HNMR、13C、MS和元素分析证实了其化学结构。结果测定了各合成化合物的抗菌活性。此外，化合物对结核分枝杆菌H37Rv菌株的抗结核活性进行了评估。化合物5c、5g和5a具有良好的抗菌特性，而5c和5g (MIC = 25 g/ml)与其他化合物相比显示出潜在的抗结核活性。利用V-Life Science MDS 4.6进行分子对接实验，补充生物学数据。结论各化合物对多种微生物均有抑菌、抗结核作用，具有一定的抑菌活性。此外，分子对接分析通过描述改进的相互作用模式证实了实验结果。

{"title":"Design, Synthesis, Anti-microbial and Molecular Docking Studies of Novel 5-Pyrazyl-2-Sulfanyl-1, 3, 4-Oxadiazole Derivatives.","authors":"R. Das, D. Mehta, Sumeet Gupta, Meenakshi Dhanawat","doi":"10.2174/2772434417666220609105755","DOIUrl":"https://doi.org/10.2174/2772434417666220609105755","url":null,"abstract":"BACKGROUND\u0000Chemical modification of Oxadiazole may lead to a potent therapeutic agent. A series of novel 5-pyrazyl-2-sulfanyl-1, 3, 4-oxadiazole derivatives (5a-g) have been synthesised utilising pyrazinoic acid as a precursor. The new oxadiazole compounds were docked against potential targets and evaluated for antibacterial and antitubercular activity.\u0000\u0000\u0000METHODS\u0000The 5-pyrazyl-2-substituted sulfanyl-1,3,4-oxadiazole derivatives (5a-g) were synthesized from the crucial intermediate 2-sulfanyl-5-pyrazyl-1,3,4-oxadiazole (4), which was prepared by treating the 2-pyrazyl hydrazide with CS2 and pyridine. IR, 1HNMR, 13C, MS and elemental analyses were used to confirm the chemical structures.\u0000\u0000\u0000RESULTS\u0000Antimicrobial activity was determined for each synthesized compound. Additionally, compounds were evaluated for antitubercular activity against the Mycobacterium Tuberculosis H37Rv strain. Compounds 5c, 5g, and 5a had a favourable antibacterial profile, while 5c and 5g (MIC = 25 g/ml) demonstrated potential antitubercular activity when compared to the other produced compounds. Molecular docking experiments using V-Life Science MDS 4.6 supplemented the biological data.\u0000\u0000\u0000CONCLUSION\u0000Each compound has been tested for antibacterial and antitubercular action against a variety of microorganism strains and exhibits considerable activity. Additionally, molecular docking analysis confirmed the experimental results by describing improved interaction patterns.","PeriodicalId":74643,"journal":{"name":"Recent advances in anti-infective drug discovery","volume":"103 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74371927","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Assessment of the anti-malarial properties of dihydroartemisinin-piperaquine phosphate solid lipid-based tablets. 磷酸二氢青蒿素-哌喹固体脂基片抗疟疾性能评价。

Recent advances in anti-infective drug discovery

Pub Date : 2022-06-06 DOI: 10.2174/2772434417666220606105822

Chime Salome A, A. A., Onunkwo Godswill C

BACKGROUNDArtemisinin based combination therapies (ACTs) typified by dihydroartemisinin-piperaquine phosphate is one of the first line drugs used in the treatment of Plasmodium falciparum malaria. However, the emergence of drug resistance to ACTs show the necessity to develop novel sustained release treatment in order to ensure maximum bioavailability.OBJECTIVESTo formulate dihydroartemisinin (DHA)-piperaquine phosphate (PQ) sustained release tablets based on solidified reverse micellar solutions (SRMS).METHODSThe SRMS was prepared by fusion using varying ratios of Phospholipon® 90H and Softisan® 154 and characterised. The tablets were prepared by using an in-house made and validated mould. The formulations were tested for uniformity of weight, hardness, friability, softening time, erosion time and in vitro-in vivo dissolution rate. Anti malarial properties were studied by modified Peter's 4-days suppressive test in mice. One-way analysis of variance (ANOVA) was used in analysis of results.RESULTSSmooth caplets, with average weight of 1300 ± 0.06 to 1312 ± 0.11 mg, drug content of 61 mg for DHA and t 450 mg for PQ. Tablets hardness ranged from 7.1 to 9.0 Kgf and softening time of 29.50 ± 1.90 min. Erosion time of 62.00 ± 2.58 to 152.00 ± 1.89 min were obtained for tablets formulated with Poloxamer 188 (Batches R2, S2 and T2) which significantly reduced the softening and erosion time (p < 0.05). In vitro release showed that optimized formulation had maximum release at 12 h. Formulations exhibited significantly higher parasitaemia clearance and in vivo absorption compared to marketed formulations at day 7 (p < 0.05).CONCLUSIONDHA-PQ tablets based on SRMS is much easier and relatively cheaper to produce than compressed tablets. They also showed exceptionally better treatment of malaria owing to their sustained release properties and improved bioavailability and is recommended to Pharmaceutical companies for further studies.

以二氢青蒿素-磷酸哌喹为代表的青蒿素为基础的联合疗法(ACTs)是治疗恶性疟原虫疟疾的一线药物之一。然而，对ACTs的耐药性的出现表明有必要开发新的缓释治疗，以确保最大的生物利用度。目的采用固化反胶束溶液(SRMS)制备双氢青蒿素(DHA)-磷酸哌喹(PQ)缓释片。方法采用不同比例的Phospholipon®90H和Softisan®154融合制备SRMS，并对其进行表征。该片剂采用自行制作并经验证的模具制备。测试了配方的重量、硬度、脆性、软化时间、侵蚀时间和体内外溶出率的均匀性。采用改良的小鼠彼得4天抑制试验研究其抗疟作用。结果分析采用单因素方差分析(ANOVA)。结果胶囊光滑，平均质量为1300±0.06 ~ 1312±0.11 mg, DHA含量为61 mg, PQ含量为450 mg。波洛沙姆188 (R2、S2、T2批)配制的片剂硬度为7.1 ~ 9.0 Kgf，软化时间为29.50±1.90 min，侵蚀时间为62.00±2.58 ~ 152.00±1.89 min，显著缩短了软化和侵蚀时间(p < 0.05)。体外释放结果表明，优化后的制剂在12 h释放量最大。第7天，与市售制剂相比，优化后的制剂的寄生虫清除率和体内吸收率显著提高(p < 0.05)。结论基于SRMS的dha - pq片剂比压缩片剂更容易生产，成本相对较低。由于它们的缓释特性和提高的生物利用度，它们还显示出对疟疾的治疗效果特别好，并被推荐给制药公司进行进一步研究。

{"title":"Assessment of the anti-malarial properties of dihydroartemisinin-piperaquine phosphate solid lipid-based tablets.","authors":"Chime Salome A, A. A., Onunkwo Godswill C","doi":"10.2174/2772434417666220606105822","DOIUrl":"https://doi.org/10.2174/2772434417666220606105822","url":null,"abstract":"BACKGROUND\u0000Artemisinin based combination therapies (ACTs) typified by dihydroartemisinin-piperaquine phosphate is one of the first line drugs used in the treatment of Plasmodium falciparum malaria. However, the emergence of drug resistance to ACTs show the necessity to develop novel sustained release treatment in order to ensure maximum bioavailability.\u0000\u0000\u0000OBJECTIVES\u0000To formulate dihydroartemisinin (DHA)-piperaquine phosphate (PQ) sustained release tablets based on solidified reverse micellar solutions (SRMS).\u0000\u0000\u0000METHODS\u0000The SRMS was prepared by fusion using varying ratios of Phospholipon® 90H and Softisan® 154 and characterised. The tablets were prepared by using an in-house made and validated mould. The formulations were tested for uniformity of weight, hardness, friability, softening time, erosion time and in vitro-in vivo dissolution rate. Anti malarial properties were studied by modified Peter's 4-days suppressive test in mice. One-way analysis of variance (ANOVA) was used in analysis of results.\u0000\u0000\u0000RESULTS\u0000Smooth caplets, with average weight of 1300 ± 0.06 to 1312 ± 0.11 mg, drug content of 61 mg for DHA and t 450 mg for PQ. Tablets hardness ranged from 7.1 to 9.0 Kgf and softening time of 29.50 ± 1.90 min. Erosion time of 62.00 ± 2.58 to 152.00 ± 1.89 min were obtained for tablets formulated with Poloxamer 188 (Batches R2, S2 and T2) which significantly reduced the softening and erosion time (p < 0.05). In vitro release showed that optimized formulation had maximum release at 12 h. Formulations exhibited significantly higher parasitaemia clearance and in vivo absorption compared to marketed formulations at day 7 (p < 0.05).\u0000\u0000\u0000CONCLUSION\u0000DHA-PQ tablets based on SRMS is much easier and relatively cheaper to produce than compressed tablets. They also showed exceptionally better treatment of malaria owing to their sustained release properties and improved bioavailability and is recommended to Pharmaceutical companies for further studies.","PeriodicalId":74643,"journal":{"name":"Recent advances in anti-infective drug discovery","volume":"32 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88173535","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Synthesis, Molecular docking and In-Vitro Antimycobacterial Studies on N'-arylidene-4-nitrobenzohydrazides. N′-芳基芳基-4-硝基苯并肼的合成、分子对接及体外抑菌研究

Recent advances in anti-infective drug discovery

Pub Date : 2022-05-31 DOI: 10.2174/1570193X19666220531154544

D. Bhosale, Suraj N. Mali, B. Thorat, Swati S Wavhal, D. Bhagat, R. M. Borade

BACKGROUNDMycobacterium tuberculosis (Mtb) is the organism that causes tuberculosis to develop (TB). In 2019, 10 million individuals worldwide contracted tuberculosis, with 1.4 million people dying from the disease each year (World Health Organization, 2021). Hydrazones-hydrazide-based drugs have been shown to be bactericidal against M. tuberculosis replication.OBJECTIVESWe herein intended to synthesize a series of acid hydrazones (3a-3l) by condensing 4-nitrobenzohydrazine with substituted aromatic acids in ethanol at room temperature.MATERIALS AND METHODSAll newly synthesized compounds were characterized by standard spectroscopic techniques. Synthesized compounds were then tested for anti-mycobacterial analysis, H37Rv strains. Molecular docking analysis was performed for three crystal structures of 1ENY, 1TED and 2FUM Mycobacterium tuberculosis receptors.RESULTSAmong all tested molecules, 3i (MIC: 50 μg/mL) and 3b (MIC: 50 μg/mL) were found to best ligands for further development of new anti-TB drug. We noticed that our proposed molecules were having higher docking scores that corresponding standard anti-TB agents such as Ciprofloxacin and Isoniazid. Synthesized compounds were found to have Drug-Likeness properties when tested with Lipinski's filter for drug-likeness.CONCLUSIONFrom our current study, we wish to propose N'-arylidene-4-nitrobenzohydrazides as anti-TB agents. Agents with such system can be developed in future for developments into active lead molecules.

背景结核分枝杆菌(Mtb)是导致结核病发展(TB)的有机体。2019年，全球有1000万人感染结核病，每年有140万人死于结核病(世界卫生组织，2021年)。肼类药物已被证明对结核分枝杆菌的复制具有杀菌作用。目的:采用4-硝基苯并肼与取代芳香酸在乙醇中室温缩合的方法合成一系列酸腙(3a-3l)。材料与方法所有新合成的化合物均采用标准光谱技术进行了表征。然后对合成的化合物进行抗分枝杆菌分析，H37Rv菌株。对结核分枝杆菌受体1ENY、1TED和2FUM三种晶体结构进行分子对接分析。结果发现3i (MIC: 50 μg/mL)和3b (MIC: 50 μg/mL)是进一步开发抗结核新药的最佳配体。我们注意到我们提出的分子比相应的标准抗结核药物如环丙沙星和异烟肼具有更高的对接分数。当用利平斯基的药物相似过滤器进行测试时，发现合成的化合物具有药物相似特性。结论从我们目前的研究来看，我们希望提出N'-芳基烯-4-硝基苯并肼作为抗结核药物。具有这种体系的试剂可以在未来发展成活性铅分子。

{"title":"Synthesis, Molecular docking and In-Vitro Antimycobacterial Studies on N'-arylidene-4-nitrobenzohydrazides.","authors":"D. Bhosale, Suraj N. Mali, B. Thorat, Swati S Wavhal, D. Bhagat, R. M. Borade","doi":"10.2174/1570193X19666220531154544","DOIUrl":"https://doi.org/10.2174/1570193X19666220531154544","url":null,"abstract":"BACKGROUND\u0000Mycobacterium tuberculosis (Mtb) is the organism that causes tuberculosis to develop (TB). In 2019, 10 million individuals worldwide contracted tuberculosis, with 1.4 million people dying from the disease each year (World Health Organization, 2021). Hydrazones-hydrazide-based drugs have been shown to be bactericidal against M. tuberculosis replication.\u0000\u0000\u0000OBJECTIVES\u0000We herein intended to synthesize a series of acid hydrazones (3a-3l) by condensing 4-nitrobenzohydrazine with substituted aromatic acids in ethanol at room temperature.\u0000\u0000\u0000MATERIALS AND METHODS\u0000All newly synthesized compounds were characterized by standard spectroscopic techniques. Synthesized compounds were then tested for anti-mycobacterial analysis, H37Rv strains. Molecular docking analysis was performed for three crystal structures of 1ENY, 1TED and 2FUM Mycobacterium tuberculosis receptors.\u0000\u0000\u0000RESULTS\u0000Among all tested molecules, 3i (MIC: 50 μg/mL) and 3b (MIC: 50 μg/mL) were found to best ligands for further development of new anti-TB drug. We noticed that our proposed molecules were having higher docking scores that corresponding standard anti-TB agents such as Ciprofloxacin and Isoniazid. Synthesized compounds were found to have Drug-Likeness properties when tested with Lipinski's filter for drug-likeness.\u0000\u0000\u0000CONCLUSION\u0000From our current study, we wish to propose N'-arylidene-4-nitrobenzohydrazides as anti-TB agents. Agents with such system can be developed in future for developments into active lead molecules.","PeriodicalId":74643,"journal":{"name":"Recent advances in anti-infective drug discovery","volume":"55 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82837193","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Mapping of new pharmacological alternatives in the face of the emergence of antibiotic resistance in COVID-19 patents treated for opportunistic respiratory bacterial pathogens. 在治疗机会性呼吸道细菌病原体的COVID-19专利中出现抗生素耐药性时，绘制新的药物替代方案

Recent advances in anti-infective drug discovery

Pub Date : 2022-05-18 DOI: 10.2174/1574891X16666220518142347

A. M. Santos, Mariana Mendonça Santos, José Adão Carvalho Nascimento Júnior, João Rafael Lisboa Rêgo Brito, Tatianny de Araújo Andrade, L. Frank, M. Serafini

BACKGROUNDThe worldwide pandemic fought by COVID-19 could emerge another type of pandemic, the increase in bacterial resistance against antibiotics. Emergency treatment based on antibioticsis a major influence in increasing this resistance. Bacteria, such as Klebsiella pneumoniae, are most affected by the indiscriminate use of antibiotics since they are resistant to most antibiotics currently available on the market.OBJECTIVEThis review aimed to evaluate patents of new drugs and formulations, for the treatment of infections caused by Klebsiella pneumoniae.METHODSThe present patent review was carried out through a specialized search database Espacenet. The selection was based on the criteria of patents published from 2010 to May 2021, in any language, and containing the keywords in title or abstract. Also, a research was performed on the PubMed database, using the inclusion criteria.RESULTSTwenty-two patents were selected for the analysis according to the aim of the study. The advance of new patents has been mostly seen in World Intellectual Property Organization, China, and United States. The results showed that the main approach was the drug association, followed by drug carriers, new isolated products, and vaccines.CONCLUSIONIt has been observed that few studies use new drug alternatives for the treatment, probably due to the higher cost of the development and lack of investments. The effectiveness and safety of these therapies depend on the acceptance, the correct prescription, and rational use of medicines. Therefore, this review can further develop new treatments as alternatives against Klebsiella pneumoniae and pneumonia caused by it.

与COVID-19作斗争的全球大流行可能出现另一种类型的大流行，即细菌对抗生素的耐药性增加。基于抗生素的紧急治疗是增加这种耐药性的主要影响因素。肺炎克雷伯菌等细菌受滥用抗生素的影响最大，因为它们对目前市场上可获得的大多数抗生素具有耐药性。目的评价治疗肺炎克雷伯菌感染的新药和制剂专利。方法通过专用检索数据库Espacenet进行专利审查。该选择基于2010年至2021年5月期间发表的专利标准，以任何语言进行，并且在标题或摘要中包含关键字。同时，利用纳入标准对PubMed数据库进行了研究。结果根据研究目的选取了22项专利进行分析。新专利的进步主要体现在世界知识产权组织、中国和美国。结果表明，主要途径是药物关联，其次是药物载体、新分离产物和疫苗。结论目前很少有研究使用新药替代治疗，可能是由于开发成本较高和缺乏投资。这些疗法的有效性和安全性取决于接受度、正确的处方和合理用药。因此，本文综述可以进一步开发新的治疗方法，作为肺炎克雷伯菌及其引起的肺炎的替代疗法。

{"title":"Mapping of new pharmacological alternatives in the face of the emergence of antibiotic resistance in COVID-19 patents treated for opportunistic respiratory bacterial pathogens.","authors":"A. M. Santos, Mariana Mendonça Santos, José Adão Carvalho Nascimento Júnior, João Rafael Lisboa Rêgo Brito, Tatianny de Araújo Andrade, L. Frank, M. Serafini","doi":"10.2174/1574891X16666220518142347","DOIUrl":"https://doi.org/10.2174/1574891X16666220518142347","url":null,"abstract":"BACKGROUND\u0000The worldwide pandemic fought by COVID-19 could emerge another type of pandemic, the increase in bacterial resistance against antibiotics. Emergency treatment based on antibioticsis a major influence in increasing this resistance. Bacteria, such as Klebsiella pneumoniae, are most affected by the indiscriminate use of antibiotics since they are resistant to most antibiotics currently available on the market.\u0000\u0000\u0000OBJECTIVE\u0000This review aimed to evaluate patents of new drugs and formulations, for the treatment of infections caused by Klebsiella pneumoniae.\u0000\u0000\u0000METHODS\u0000The present patent review was carried out through a specialized search database Espacenet. The selection was based on the criteria of patents published from 2010 to May 2021, in any language, and containing the keywords in title or abstract. Also, a research was performed on the PubMed database, using the inclusion criteria.\u0000\u0000\u0000RESULTS\u0000Twenty-two patents were selected for the analysis according to the aim of the study. The advance of new patents has been mostly seen in World Intellectual Property Organization, China, and United States. The results showed that the main approach was the drug association, followed by drug carriers, new isolated products, and vaccines.\u0000\u0000\u0000CONCLUSION\u0000It has been observed that few studies use new drug alternatives for the treatment, probably due to the higher cost of the development and lack of investments. The effectiveness and safety of these therapies depend on the acceptance, the correct prescription, and rational use of medicines. Therefore, this review can further develop new treatments as alternatives against Klebsiella pneumoniae and pneumonia caused by it.","PeriodicalId":74643,"journal":{"name":"Recent advances in anti-infective drug discovery","volume":"14 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-05-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79598936","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

New Frontier in Drugs for Antivirals in Disorders of The Respiratory System. 呼吸系统疾病抗病毒药物的新进展。

Recent advances in anti-infective drug discovery

Pub Date : 2022-04-16 DOI: 10.2174/1574891X16666220416164740

Hai-long Zhang, Yongxia Li, Ai-Feng Zhou, Yiqian Li

BACKGROUNDCOVID-19 is still soaring around the world, and the new delta COVID-19 variant is on the rise and spreading around the world.OBJECTIVEto show development of therapeutic strategy of antiviruses in drugs for antivirals in disorders of the respiratory system, we conduct patent analysis surrounding drugs for antivirals in disorders of the respiratory system.MATERIALS AND METHODEuropean granted patents filed from January 2002 to June 2021 were analyzed. We use a combination of International patent classification (IPC) "A61p31/12" (antivirals) and "A61p11/00" (drugs for disorders of the respiratory system) to identify relevant European patent documents.RESULTSOur study showed that R&D of drugs for antivirals in disorders of the respiratory systems was decreasing over past 20 years. Chemical drugs show more variety in structures and no a common feature for this drug development. The chemical drugs or herbal medicines were much earlier appeared than biological products in research and development. In addition, large global companies play a leading role in developing kinase inhibitors as chemical drugs.CONCLUSIONThere are three strategies for developing drugs for antivirals in disorders of the respiratory system, including chemical drugs, herbal medicines or natural products, and biological products. Herbal medicines may provide a new insight and approach for developing drugs for antivirals in disorders of the respiratory system. A combination of chemical drugs and natural products may be a therapeutic method for treating patients with COVID-19.

背景COVID-19在全球范围内仍在飙升，新型delta型COVID-19正在崛起并在全球蔓延。目的探讨呼吸系统疾病抗病毒药物抗病毒治疗策略的研究进展，对呼吸系统疾病抗病毒药物进行专利分析。对2002年1月至2021年6月期间申请的材料和欧洲授权专利进行了分析。我们结合了国际专利分类(IPC)“A61p31/12”(抗病毒药物)和“A61p11/00”(呼吸系统疾病药物)识别相关欧洲专利文件。结果我们的研究表明，在过去的20年里，用于治疗呼吸系统疾病的抗病毒药物的研发呈下降趋势。化学药物在结构上表现出更多的多样性，并且在这类药物的开发中没有一个共同的特征。化学药物或中草药的研究开发要比生物制品早得多。此外，大型跨国公司在开发激酶抑制剂作为化学药物方面发挥着主导作用。结论呼吸系统疾病抗病毒药物的开发策略主要有化学药物、草药或天然药物和生物制剂三种。草药可能为开发呼吸系统疾病的抗病毒药物提供新的见解和途径。化学药物和天然产物的结合可能是治疗COVID-19患者的一种治疗方法。

{"title":"New Frontier in Drugs for Antivirals in Disorders of The Respiratory System.","authors":"Hai-long Zhang, Yongxia Li, Ai-Feng Zhou, Yiqian Li","doi":"10.2174/1574891X16666220416164740","DOIUrl":"https://doi.org/10.2174/1574891X16666220416164740","url":null,"abstract":"BACKGROUND\u0000COVID-19 is still soaring around the world, and the new delta COVID-19 variant is on the rise and spreading around the world.\u0000\u0000\u0000OBJECTIVE\u0000to show development of therapeutic strategy of antiviruses in drugs for antivirals in disorders of the respiratory system, we conduct patent analysis surrounding drugs for antivirals in disorders of the respiratory system.\u0000\u0000\u0000MATERIALS AND METHOD\u0000European granted patents filed from January 2002 to June 2021 were analyzed. We use a combination of International patent classification (IPC) \"A61p31/12\" (antivirals) and \"A61p11/00\" (drugs for disorders of the respiratory system) to identify relevant European patent documents.\u0000\u0000\u0000RESULTS\u0000Our study showed that R&D of drugs for antivirals in disorders of the respiratory systems was decreasing over past 20 years. Chemical drugs show more variety in structures and no a common feature for this drug development. The chemical drugs or herbal medicines were much earlier appeared than biological products in research and development. In addition, large global companies play a leading role in developing kinase inhibitors as chemical drugs.\u0000\u0000\u0000CONCLUSION\u0000There are three strategies for developing drugs for antivirals in disorders of the respiratory system, including chemical drugs, herbal medicines or natural products, and biological products. Herbal medicines may provide a new insight and approach for developing drugs for antivirals in disorders of the respiratory system. A combination of chemical drugs and natural products may be a therapeutic method for treating patients with COVID-19.","PeriodicalId":74643,"journal":{"name":"Recent advances in anti-infective drug discovery","volume":"55 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78328659","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Meet the Editorial Board Member 认识编辑委员会成员

Recent advances in anti-infective drug discovery

Pub Date : 2022-04-01 DOI: 10.2174/277243441701220830144428

S. Ghafourian

引用次数: 0

Herbal Phytomedicine 'Irisolidone' in chronic diseases: Biological Efficacy and pharmacological activity. 植物草药“伊瑞isolidone”在慢性疾病中的生物学功效和药理活性。

Recent advances in anti-infective drug discovery

Pub Date : 2022-03-04 DOI: 10.2174/1574891x16666220304231934

D. Patel

BACKGROUNDPlant derived products have been used in the medicine as a source of bioactive molecules due to its therapeutic potential. Nowadays plants derived products have been used for the development of novel drug leads. Polyphenols are an important class of secondary metabolites found to be present in plant material and their derived products. Polyphenols are having an important role in the nutrition for human beings. It also has a significant role in plant resistance against pests and diseases. Scientific studies have proven the biological importance of flavonoids in medicine and other allied health sectors. Anti-oxidant, analgesic, anti-microbial, anti-inflammatory, anti-viral, anti-tumor and anti-allergic activities are the important pharmacological features of flavonoids. Irisolidone is an important isoflavone found to be present in Pueraria lobata flowers.METHODSIn order to know the medicinal importance and therapeutic benefit of irisolidone, numerous scientific research data have been collected from Google, Google Scholar, PubMed, Science Direct and Scopus. Pharmacological activities scientific data of irisolidone has been collected and analyzed in the present works to know the health beneficial aspects of irisolidone. Detailed pharmacological activities of irisolidone have been investigated through scientific data analysis of scientific research works.RESULTSScientific research data analysis of irisolidone revealed the anti-inflammatory, anti-angiogenic, anti-cancer, anti-platelet, anti-oxidant, anti-hyperlipidemic, immunomodulating, hepatoprotective and estrogenic activities. However biological effect of irisolidone on gastric system, aldose reductase enzymes, malignant gliomas and JC virus has been also investigated. Scientific data analysis revealed the significance of analytical tools for separation and identification of irisolidone.CONCLUSIONPresent work signified the biological importance and therapeutic potential of irisolidone in the medicine.

背景:植物衍生产品由于其治疗潜力已被用作生物活性分子的来源。目前，植物源性产品已被广泛用于新型药物先导物的开发。多酚是一类重要的次生代谢产物，存在于植物材料及其衍生产品中。多酚类物质在人体营养中起着重要的作用。它在植物抗病虫害方面也有重要作用。科学研究已经证明了类黄酮在医学和其他相关卫生部门的生物学重要性。抗氧化、镇痛、抗微生物、抗炎、抗病毒、抗肿瘤和抗过敏是黄酮类化合物的重要药理特性。鸢尾甾酮是葛根花中发现的一种重要异黄酮。方法通过Google、Google Scholar、PubMed、Science Direct和Scopus等网站收集了大量的科学研究数据，了解了伊瑞isolidone的药用价值和治疗益处。本工作收集和分析了伊里索拉酮的药理活性科学数据，以了解伊里索拉酮的保健益处。通过对科研工作的科学数据分析，详细地研究了伊里斯酮的药理活性。结果科研数据分析显示，利索里酮具有抗炎、抗血管生成、抗癌、抗血小板、抗氧化、抗高脂血症、免疫调节、保肝和雌激素等活性。然而，对胃系统、醛糖还原酶、恶性胶质瘤和JC病毒的生物学效应也有研究。科学的数据分析揭示了分析工具在分离鉴定中应用的重要意义。结论本工作表明了伊里斯酮在医学上的生物学意义和治疗潜力。

{"title":"Herbal Phytomedicine 'Irisolidone' in chronic diseases: Biological Efficacy and pharmacological activity.","authors":"D. Patel","doi":"10.2174/1574891x16666220304231934","DOIUrl":"https://doi.org/10.2174/1574891x16666220304231934","url":null,"abstract":"BACKGROUND\u0000Plant derived products have been used in the medicine as a source of bioactive molecules due to its therapeutic potential. Nowadays plants derived products have been used for the development of novel drug leads. Polyphenols are an important class of secondary metabolites found to be present in plant material and their derived products. Polyphenols are having an important role in the nutrition for human beings. It also has a significant role in plant resistance against pests and diseases. Scientific studies have proven the biological importance of flavonoids in medicine and other allied health sectors. Anti-oxidant, analgesic, anti-microbial, anti-inflammatory, anti-viral, anti-tumor and anti-allergic activities are the important pharmacological features of flavonoids. Irisolidone is an important isoflavone found to be present in Pueraria lobata flowers.\u0000\u0000\u0000METHODS\u0000In order to know the medicinal importance and therapeutic benefit of irisolidone, numerous scientific research data have been collected from Google, Google Scholar, PubMed, Science Direct and Scopus. Pharmacological activities scientific data of irisolidone has been collected and analyzed in the present works to know the health beneficial aspects of irisolidone. Detailed pharmacological activities of irisolidone have been investigated through scientific data analysis of scientific research works.\u0000\u0000\u0000RESULTS\u0000Scientific research data analysis of irisolidone revealed the anti-inflammatory, anti-angiogenic, anti-cancer, anti-platelet, anti-oxidant, anti-hyperlipidemic, immunomodulating, hepatoprotective and estrogenic activities. However biological effect of irisolidone on gastric system, aldose reductase enzymes, malignant gliomas and JC virus has been also investigated. Scientific data analysis revealed the significance of analytical tools for separation and identification of irisolidone.\u0000\u0000\u0000CONCLUSION\u0000Present work signified the biological importance and therapeutic potential of irisolidone in the medicine.","PeriodicalId":74643,"journal":{"name":"Recent advances in anti-infective drug discovery","volume":"16 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89670912","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Structural Insights and Pharmaceutical Relevance of Plumbagin in Parasitic Disorders: A Comprehensive Review. 寄生虫疾病中白桦素的结构见解和药物相关性:综述。

Recent advances in anti-infective drug discovery

Pub Date : 2022-01-01 DOI: 10.2174/2772434417666220905121531

Amrat Pal Singh, Alok Sharma

Recently, natural products have been became the center of attraction for the scientific society and exploration of their biologically abilities is proceeding continuously. In search for novel antiparasitic agents with an objective of protecting humans from parasitic infections, the present work was focused on naphthoquinones possessing antiparasitic activity. Among naphthoquinones, plumbagin is one of the secondary metabolites exhibiting diverse biological properties such as antibacterial, antimalarial, antiinflammatory, insecticidal and antiparasitic. Plumbagin is reported to have antischistosomiasis, anti-haemonchosis, anti-fascioliasis, antiotoacariasis, anti-leishmaniasis, antimalaria, antiallergic and anthelmintic activities. Besides, various methods of extraction of plumbagin from different methods, their effectiveness against different parasites, and the structure-activity relationship reported by different researchers. This work highlight on recent advancements in the phytochemistry of plumbagin, studies associated with various biological activities. The structure-activity relationship studies have also been summarized. To conclude, present review could be beneficial for the scientific community to get better insight into medicinal research of plumbagin and may provide a new horizon for the rational design of plumbagin based compounds.

近年来，天然产物已成为科学界关注的焦点，对其生物学能力的探索也在不断进行。为了寻找新的抗寄生虫药物以保护人类免受寄生虫感染，目前的工作主要集中在具有抗寄生虫活性的萘醌类药物上。在萘醌类化合物中，白丹素是一种具有抗菌、抗疟、抗炎、杀虫、抗寄生虫等多种生物学特性的次生代谢产物。据报道，白桦素具有抗血吸虫病、抗血液病、抗片形吸虫病、抗耳螨病、抗利什曼病、抗疟疾、抗过敏和驱虫活性。此外，还介绍了不同提取方法提取白桦白素的方法、对不同寄生虫的药效以及不同研究者报道的构效关系。本文重点介绍了近年来白桦白素的植物化学研究进展及其与各种生物活性的关系。并对构效关系的研究进行了综述。综上所述，本文综述将有助于科学界更好地了解白桦素的药用研究，并为白桦素类化合物的合理设计提供新的思路。

{"title":"Structural Insights and Pharmaceutical Relevance of Plumbagin in Parasitic Disorders: A Comprehensive Review.","authors":"Amrat Pal Singh, Alok Sharma","doi":"10.2174/2772434417666220905121531","DOIUrl":"https://doi.org/10.2174/2772434417666220905121531","url":null,"abstract":"Recently, natural products have been became the center of attraction for the scientific society and exploration of their biologically abilities is proceeding continuously. In search for novel antiparasitic agents with an objective of protecting humans from parasitic infections, the present work was focused on naphthoquinones possessing antiparasitic activity. Among naphthoquinones, plumbagin is one of the secondary metabolites exhibiting diverse biological properties such as antibacterial, antimalarial, antiinflammatory, insecticidal and antiparasitic. Plumbagin is reported to have antischistosomiasis, anti-haemonchosis, anti-fascioliasis, antiotoacariasis, anti-leishmaniasis, antimalaria, antiallergic and anthelmintic activities. Besides, various methods of extraction of plumbagin from different methods, their effectiveness against different parasites, and the structure-activity relationship reported by different researchers. This work highlight on recent advancements in the phytochemistry of plumbagin, studies associated with various biological activities. The structure-activity relationship studies have also been summarized. To conclude, present review could be beneficial for the scientific community to get better insight into medicinal research of plumbagin and may provide a new horizon for the rational design of plumbagin based compounds.","PeriodicalId":74643,"journal":{"name":"Recent advances in anti-infective drug discovery","volume":"17 3","pages":"187-198"},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10394754","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Medicinal Importance, Pharmacological Activities, and Analytical Aspects of Strictinin: A Mini-Review. 药用重要性，药理活性和分析方面:一个小型综述。

Recent advances in anti-infective drug discovery

Pub Date : 2022-01-01 DOI: 10.2174/2772434417666220628153913

Dinesh Kumar Patel

Background: Plants and their derived products have been used in history as food and medicine. Plant materials are rich sources of fiber, minerals, vitamins, and bioactive phytochemicals, which are useful for human beings. Strictinin is an important phytoconstituent of green tea.

Methods: Present work mainly focuses on the biological importance, therapeutic potential, and pharmacological activities of strictinin in medicine. Numerous scientific data have been collected from various literature databases such as Google Scholar, Science Direct, PubMed, and Scopus database in order to realize the health beneficial potential of strictinin. Pharmacological data has been collected and analyzed in the present work to find the effectiveness of strictinin against human disorders and complications. Analytical data of strictinin has been also collected and analyzed in the present work.

Results: Scientific data analysis revealed the biological importance of strictinin in medicine. Scientific data analysis signified the therapeutic benefit of strictinin mainly due to its anticancer, antimicrobial, antibacterial, antiviral, and antioxidant activity. However, enzymatic activities, cytotoxicity, effectiveness on skin disorders, and osteogenic potential of strictinin have also been discussed. Analytical data revealed the importance of modern analytical techniques in medicine for the separation, identification, and isolation of strictinin.

Conclusion: Present work signified the biological importance and therapeutic benefits of strictinin in medicine and other allied health sectors.

背景:植物及其衍生产品在历史上被用作食物和药物。植物材料是纤维、矿物质、维生素和生物活性植物化学物质的丰富来源，对人类非常有益。Strictinin是绿茶中一种重要的植物成分。方法:从生物学意义、治疗潜力和药理作用等方面对其进行了综述。从Google Scholar、Science Direct、PubMed、Scopus等文献数据库中收集了大量的科学数据，以了解strictinin对健康的有益潜力。在本工作中收集和分析了药理学数据，以发现strictinin对人类疾病和并发症的有效性。本工作还收集和分析了缩窄酶的分析数据。结果:科学的数据分析揭示了紧缩蛋白在医学上的生物学意义。科学数据分析表明，紧缩蛋白具有抗癌、抗菌、抗菌、抗病毒和抗氧化作用。然而，酶活性、细胞毒性、对皮肤疾病的有效性和成骨潜力也被讨论过。分析数据揭示了现代分析技术在分离、鉴定和分离严格蛋白方面的重要性。结论:本工作表明了严格限制蛋白在医学和其他相关卫生部门的生物学重要性和治疗效益。

{"title":"Medicinal Importance, Pharmacological Activities, and Analytical Aspects of Strictinin: A Mini-Review.","authors":"Dinesh Kumar Patel","doi":"10.2174/2772434417666220628153913","DOIUrl":"https://doi.org/10.2174/2772434417666220628153913","url":null,"abstract":"Background: Plants and their derived products have been used in history as food and medicine. Plant materials are rich sources of fiber, minerals, vitamins, and bioactive phytochemicals, which are useful for human beings. Strictinin is an important phytoconstituent of green tea.Methods: Present work mainly focuses on the biological importance, therapeutic potential, and pharmacological activities of strictinin in medicine. Numerous scientific data have been collected from various literature databases such as Google Scholar, Science Direct, PubMed, and Scopus database in order to realize the health beneficial potential of strictinin. Pharmacological data has been collected and analyzed in the present work to find the effectiveness of strictinin against human disorders and complications. Analytical data of strictinin has been also collected and analyzed in the present work.Results: Scientific data analysis revealed the biological importance of strictinin in medicine. Scientific data analysis signified the therapeutic benefit of strictinin mainly due to its anticancer, antimicrobial, antibacterial, antiviral, and antioxidant activity. However, enzymatic activities, cytotoxicity, effectiveness on skin disorders, and osteogenic potential of strictinin have also been discussed. Analytical data revealed the importance of modern analytical techniques in medicine for the separation, identification, and isolation of strictinin.Conclusion: Present work signified the biological importance and therapeutic benefits of strictinin in medicine and other allied health sectors.","PeriodicalId":74643,"journal":{"name":"Recent advances in anti-infective drug discovery","volume":" ","pages":"86-94"},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40406437","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0